MedPath

FARMINTERPRAISEZ, OOO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:0
Completed:9

Trial Phases

2 Phases

Phase 1:4
Phase 2:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 2
7 (63.6%)
Phase 1
4 (36.4%)

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Phase 2
Not yet recruiting
Conditions
Cystitis
Interventions
Drug: XC243 50 mg
Drug: Placebo
Drug: XC243 25 mg
Drug: XC243 75 mg
First Posted Date
2024-04-30
Last Posted Date
2024-04-30
Lead Sponsor
PHARMENTERPRISES LLC
Target Recruit Count
280
Registration Number
NCT06391164
Locations
🇷🇺

Unimed-S Cjsc, Moscow, Russian Federation

🇷🇺

LLC "Research Center Eco-Safety", Saint Petersburg, Russian Federation

🇷🇺

St. Petersburg State Budgetary Healthcare Institution "City Polyclinic № 112", Saint Petersburg, Russian Federation

and more 4 locations

Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Doses of XC243 After Single and Multiple Oral Administration in Healthy Volunteers.

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo single
Drug: XC243 200 mg multiple
Drug: XC243 100 mg single
Drug: XC243 200 mg single-dose food effect
Drug: Placebo single-dose food effect
Drug: Placebo multiple
Drug: XC243 50 mg single
First Posted Date
2022-11-28
Last Posted Date
2023-11-18
Lead Sponsor
PHARMENTERPRISES LLC
Target Recruit Count
38
Registration Number
NCT05628116
Locations
🇷🇺

LLS X7 Clinical Research, Saint Petersburg, Russian Federation

Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19

Phase 2
Conditions
SARS-CoV-2 Infection
Lung Fibrosis
Interventions
First Posted Date
2022-08-25
Last Posted Date
2022-08-25
Lead Sponsor
PHARMENTERPRISES LLC
Target Recruit Count
412
Registration Number
NCT05516550

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia

Phase 2
Completed
Conditions
Fibrosis Lung
SARS-CoV-2 Infection
Interventions
Drug: Placebo
First Posted Date
2020-08-26
Last Posted Date
2021-04-05
Lead Sponsor
PHARMENTERPRISES LLC
Target Recruit Count
60
Registration Number
NCT04527354
Locations
🇷🇺

Federal State-Funded Research Institution "Research Institute of Complex Cardiovascular Diseases", Kemerovo, Russian Federation

🇷🇺

Federal State Budgetary Institution "N.N. Burdenko Military Clinical Hospital", Moscow, Russian Federation

🇷🇺

SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow, Russian Federation

and more 5 locations

Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers

Phase 1
Completed
Conditions
Metabolic Syndrome
Interventions
First Posted Date
2020-06-11
Last Posted Date
2020-06-17
Lead Sponsor
PHARMENTERPRISES LLC
Target Recruit Count
20
Registration Number
NCT04428593
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.